Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up

Thursday, 24 November, 2022 - 15:00 to 16:30

Abstract

People with an opioid use disorder have lower life satisfaction compared to the general population. Our study examines changes in life satisfaction during short- and longer-term treatment with extended-release naltrexone (XR-NTX). In the open-label, 12-week clinical trial, 159 participants were randomized to either monthly XR-NTX or daily buprenorphine-naloxone (BP-NLX). In the subsequent 36-week follow-up study, participants either continued or switched to XR-NTX. Data on the Temporary Satisfaction with Life (TSWL) and illicit opioid use were collected every fourth week. Changes in life satisfaction were assessed using a linear mixed model and growth mixture model. The relationship between life satisfaction and opioid use was assessed using a linear mixed model. In the trial, TSWL scores were significantly higher in the XR-NTX group at week 4 (p=0.013) and week 8 (p=0.002) compared with the BP-NLX group. In the follow-up period, TSWL scores were significantly higher in the XR-NTX-continuing group at week 16 (p=0.031) and week 48 (p=0.025). A lower mean TSWL score was associated with increased opioid use. Low and high life satisfaction groups were identified. In the trial period, TSWL scores showed a significant increase from baseline up to week 12 in both groups, p<0.001 and p=0.011 in the low and high life satisfaction group, respectively. In the follow-up period, TSWL scores showed a significant increase from week 16 to 48 (p=0.003) in the high life satisfaction group, while values remained consistently low in the low life satisfaction group. Higher life satisfaction was associated with XR-NTX treatment compared to BP-NLX. Most participants reported lower baseline life satisfaction that did not change with longer treatment. Low or decreasing life satisfaction has been associated with frequent illicit opioid use.

Speakers

Type

Tracks

Part of session